JP2014506240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506240A5 JP2014506240A5 JP2013543530A JP2013543530A JP2014506240A5 JP 2014506240 A5 JP2014506240 A5 JP 2014506240A5 JP 2013543530 A JP2013543530 A JP 2013543530A JP 2013543530 A JP2013543530 A JP 2013543530A JP 2014506240 A5 JP2014506240 A5 JP 2014506240A5
- Authority
- JP
- Japan
- Prior art keywords
- iii
- nanoparticle composition
- metal body
- less
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000010949 copper Substances 0.000 claims 94
- 239000002105 nanoparticle Substances 0.000 claims 50
- 238000000034 method Methods 0.000 claims 38
- 229910052751 metal Inorganic materials 0.000 claims 32
- 239000002184 metal Substances 0.000 claims 32
- 229910052733 gallium Inorganic materials 0.000 claims 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 12
- 150000001768 cations Chemical class 0.000 claims 12
- 229910052802 copper Inorganic materials 0.000 claims 12
- 229910052688 Gadolinium Inorganic materials 0.000 claims 10
- 229910052765 Lutetium Inorganic materials 0.000 claims 10
- 229910052742 iron Inorganic materials 0.000 claims 10
- 229910052713 technetium Inorganic materials 0.000 claims 10
- 229910052716 thallium Inorganic materials 0.000 claims 10
- 229910052692 Dysprosium Inorganic materials 0.000 claims 9
- 229910052804 chromium Inorganic materials 0.000 claims 9
- 229910052748 manganese Inorganic materials 0.000 claims 9
- 229910052759 nickel Inorganic materials 0.000 claims 9
- 229910052727 yttrium Inorganic materials 0.000 claims 9
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims 8
- 239000002738 chelating agent Substances 0.000 claims 8
- 238000005538 encapsulation Methods 0.000 claims 7
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 4
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 4
- 239000002555 ionophore Substances 0.000 claims 4
- 230000000236 ionophoric effect Effects 0.000 claims 4
- 229960003330 pentetic acid Drugs 0.000 claims 4
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical group C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 claims 3
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 claims 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 3
- 125000002091 cationic group Chemical group 0.000 claims 3
- BJAJDJDODCWPNS-UHFFFAOYSA-N dotp Chemical compound O=C1N2CCOC2=NC2=C1SC=C2 BJAJDJDODCWPNS-UHFFFAOYSA-N 0.000 claims 3
- 230000003204 osmotic effect Effects 0.000 claims 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 2
- YDVODBIDDSGKAD-UHFFFAOYSA-N 1,4,7,11-tetrazacyclotetradecane Chemical compound C1CNCCCNCCNCCNC1 YDVODBIDDSGKAD-UHFFFAOYSA-N 0.000 claims 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 2
- HHLZCENAOIROSL-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)CN1CCNCCN(CC(O)=O)CCN(CC(O)=O)CC1 HHLZCENAOIROSL-UHFFFAOYSA-N 0.000 claims 2
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 claims 2
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 claims 2
- 239000010931 gold Substances 0.000 claims 2
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 238000003325 tomography Methods 0.000 claims 2
- LADZJJOUGVGJHM-UHFFFAOYSA-N 1,4,7,10-tetrazacyclotridecane Chemical compound C1CNCCNCCNCCNC1 LADZJJOUGVGJHM-UHFFFAOYSA-N 0.000 claims 1
- KUFDRRWNPNXBRF-UHFFFAOYSA-N 1,4,8,12-tetrazacyclopentadecane Chemical compound C1CNCCCNCCNCCCNC1 KUFDRRWNPNXBRF-UHFFFAOYSA-N 0.000 claims 1
- TWMXRTUIOCTFNL-UHFFFAOYSA-N 1,5,8,12-tetrazabicyclo[10.2.2]hexadecane Chemical group C1CN2CCN1CCCNCCNCCC2 TWMXRTUIOCTFNL-UHFFFAOYSA-N 0.000 claims 1
- YXPRJLINFVQPDT-UHFFFAOYSA-N 1,5,9,13-tetrazacyclohexadecane Chemical compound C1CNCCCNCCCNCCCNC1 YXPRJLINFVQPDT-UHFFFAOYSA-N 0.000 claims 1
- XDLOGHYCUQYEKA-UHFFFAOYSA-N 2-(1,4,7,10-tetrazacyclododec-1-yl)acetic acid Chemical compound OC(=O)CN1CCNCCNCCNCC1 XDLOGHYCUQYEKA-UHFFFAOYSA-N 0.000 claims 1
- HDKPQQZMQBYEHX-UHFFFAOYSA-N 2-(4,8,11-triaza-1-azoniacyclotetradec-1-yl)acetate Chemical compound OC(=O)CN1CCCNCCNCCCNCC1 HDKPQQZMQBYEHX-UHFFFAOYSA-N 0.000 claims 1
- SPSJFVXUOKRIGT-UHFFFAOYSA-N 2-[7-(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)CN1CCNCCN(CC(O)=O)CCNCC1 SPSJFVXUOKRIGT-UHFFFAOYSA-N 0.000 claims 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 1
- 229910052772 Samarium Inorganic materials 0.000 claims 1
- 229910052771 Terbium Inorganic materials 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 claims 1
- 229910052767 actinium Inorganic materials 0.000 claims 1
- QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 claims 1
- 229910052787 antimony Inorganic materials 0.000 claims 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 claims 1
- 229910052789 astatine Inorganic materials 0.000 claims 1
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 claims 1
- 229910052788 barium Inorganic materials 0.000 claims 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 1
- 229910052793 cadmium Inorganic materials 0.000 claims 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- 150000001783 ceramides Chemical class 0.000 claims 1
- 101150040681 cho1 gene Proteins 0.000 claims 1
- 229910017052 cobalt Inorganic materials 0.000 claims 1
- 239000010941 cobalt Substances 0.000 claims 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 229910052738 indium Inorganic materials 0.000 claims 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 229910052746 lanthanum Inorganic materials 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000030648 nucleus localization Effects 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 229910052705 radium Inorganic materials 0.000 claims 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 claims 1
- 229910052702 rhenium Inorganic materials 0.000 claims 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims 1
- 229910052707 ruthenium Inorganic materials 0.000 claims 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims 1
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 1
- 150000003408 sphingolipids Chemical class 0.000 claims 1
- 229910052712 strontium Inorganic materials 0.000 claims 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims 1
- 229910052714 tellurium Inorganic materials 0.000 claims 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 claims 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 claims 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 claims 1
- NAWDYIZEMPQZHO-AHCXROLUSA-N ytterbium-169 Chemical compound [169Yb] NAWDYIZEMPQZHO-AHCXROLUSA-N 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201070542 | 2010-12-14 | ||
| DKPA201070542 | 2010-12-14 | ||
| US201161434070P | 2011-01-19 | 2011-01-19 | |
| EP11151372.7 | 2011-01-19 | ||
| EP11151372 | 2011-01-19 | ||
| US61/434,070 | 2011-01-19 | ||
| PCT/DK2011/050479 WO2012079582A1 (en) | 2010-12-14 | 2011-12-14 | Entrapment of radionuclides in nanoparticle compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014506240A JP2014506240A (ja) | 2014-03-13 |
| JP2014506240A5 true JP2014506240A5 (enExample) | 2015-02-05 |
| JP5947807B2 JP5947807B2 (ja) | 2016-07-06 |
Family
ID=45445682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013543530A Expired - Fee Related JP5947807B2 (ja) | 2010-12-14 | 2011-12-14 | ナノ粒子組成物への放射性核種の封入 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9226984B2 (enExample) |
| EP (1) | EP2651447B1 (enExample) |
| JP (1) | JP5947807B2 (enExample) |
| KR (1) | KR20140092226A (enExample) |
| AU (1) | AU2011344865B2 (enExample) |
| BR (1) | BR112013014735A2 (enExample) |
| CA (1) | CA2821024A1 (enExample) |
| DK (1) | DK2651447T3 (enExample) |
| RU (1) | RU2013132610A (enExample) |
| WO (1) | WO2012079582A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013249307B2 (en) | 2012-04-17 | 2017-11-09 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for non-invasive imaging |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| US9993427B2 (en) * | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
| WO2015061592A1 (en) * | 2013-10-23 | 2015-04-30 | Merrimack Pharmaceuticals, Inc. | Liposomes for non-invasive imaging and drug delivery |
| TW201615229A (zh) * | 2014-10-23 | 2016-05-01 | 行政院原子能委員會核能研究所 | 製備放射標靶藥物的套件及放射標靶藥物之製造方法 |
| MX381655B (es) | 2015-05-04 | 2025-03-13 | Versantis AG | Metodo para preparar vesiculas con gradiente de ph de transmembrana. |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| PL3337467T3 (pl) | 2015-08-20 | 2021-06-14 | Ipsen Biopharm Ltd. | Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu |
| PL3337478T5 (pl) | 2015-08-21 | 2026-05-04 | Ipsen Biopharm Ltd. | Kombinacja leków obejmująca liposomalny irynotekan, oksaliplatynę, 5-fluorouracyl i leukoworynę do leczenia nowotworu trzustki z przerzutami |
| RU2599462C1 (ru) * | 2015-09-22 | 2016-10-10 | Общество с ограниченной ответственностью "БИОТЕХНОЛОГИЯ" (ООО "БИОТЕХНОЛОГИЯ") | Способ полисигнальной активации апоптоза клеток злокачественных солидных опухолей |
| AU2016340153B2 (en) | 2015-10-16 | 2022-06-02 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
| EP3354270A4 (en) * | 2016-10-21 | 2019-04-24 | Obshestvo S Ogranichennoi Otvetstvennost'yu "Biotehnologiya" | METHOD FOR ACTIVATION OF APOPTOSIS OF CELLS WITH MULTIPLE SIGNALING OF SOLID MALIGNANT TUMORS |
| EP3535026A1 (en) | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Limited | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| WO2019183724A1 (en) | 2018-03-26 | 2019-10-03 | Triumf, A Joint Venture Of The Governors Of The University Of Alberta, The University Of British Columbia, The Governors Of The University Of Calgary, Carleton University, University Of Guelph, Mcmaster University, University Of Manitoba, Universite De Montreal, Queen's University, University Of Reg | Systems, apparatus and methods for separating actinium, radium, and thorium |
| CN109063231B (zh) * | 2018-06-15 | 2023-06-27 | 中国核电工程有限公司 | 基于GUM导则的核素不确定度对临界系统keff影响的评定方法 |
| US20220118116A1 (en) * | 2019-01-29 | 2022-04-21 | The Johns Hopkins University | Adhesive/adsorption switch on nanoparticles to increase tumor uptake and delay tumor clearance |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| WO2023183559A1 (en) * | 2022-03-24 | 2023-09-28 | The Brigham And Women's Hospital, Inc. | Engineered ionophores for transport of metal ions |
| WO2024258223A1 (ko) * | 2023-06-14 | 2024-12-19 | 주식회사 지티아이바이오사이언스 | 방사성 동위원소를 포함하는 나노입자 조성물을 제조하는 장치 및 이의 제조 방법 |
| FR3156312A1 (fr) * | 2023-12-08 | 2025-06-13 | Aken Medical | Nanoparticules radioactives de type cœur/enveloppes utiles en radiothérapie ciblée |
| FR3156311A1 (fr) * | 2023-12-08 | 2025-06-13 | Aken Medical | Nanoparticules radioactives de type cœur/enveloppe utiles en radiothérapie ciblée |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4310506A (en) | 1979-02-22 | 1982-01-12 | California Institute Of Technology | Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species |
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US5736155A (en) | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US4753788A (en) * | 1985-01-31 | 1988-06-28 | Vestar Research Inc. | Method for preparing small vesicles using microemulsification |
| US5622713A (en) | 1985-09-17 | 1997-04-22 | The Regents Of The University Of California | Method of detoxifying animal suffering from overdose |
| DE3880691T2 (de) | 1987-11-04 | 1993-08-12 | Vestar Inc | Zusammensetzung und verfahren zur anwendung von in liposomen eingeschlossenen verbindungen in der neutroneneinfangtherapie von tumoren. |
| US5258499A (en) | 1988-05-16 | 1993-11-02 | Vestar, Inc. | Liposome targeting using receptor specific ligands |
| US5688488A (en) | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5525232A (en) | 1990-03-02 | 1996-06-11 | The Liposome Company, Inc. | Method for entrapment of cationic species in lemellar vesicles |
| JPH075561B2 (ja) | 1991-12-17 | 1995-01-25 | 工業技術院長 | α−アミノ酸のジアミド誘導体 |
| CA2093381A1 (en) * | 1992-04-07 | 1993-10-08 | Hideyuki Sawahara | Liposome formulation and process for production thereof |
| US5837282A (en) * | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6106858A (en) * | 1997-09-08 | 2000-08-22 | Skyepharma, Inc. | Modulation of drug loading in multivescular liposomes |
| US5945502A (en) | 1997-11-13 | 1999-08-31 | Xerox Corporation | Electroluminescent polymer compositions and processes thereof |
| NO312708B1 (no) | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
| CA2455598A1 (en) * | 2001-07-27 | 2003-02-13 | Targesome, Inc. | Lipid constructs as therapeutic and imaging agents |
| US20050118249A1 (en) | 2001-11-13 | 2005-06-02 | Murray Webb | Lipid carrier compositions and methods for improved drug retention |
| WO2003072142A1 (fr) * | 2002-02-26 | 2003-09-04 | Amato Pharmaceutical Products, Ltd. | Procede d'encapsulation de complexes metalliques dans des liposomes |
| EP1603535A4 (en) | 2003-03-18 | 2008-10-15 | Ethicon Inc | AROMATASE HEMMER DIAGNOSIS AND THERAPY |
| EP1616182A4 (en) | 2003-03-18 | 2008-04-16 | Ethicon Inc | ENZYMERSATZ THERAPY WITH 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2 |
| JP2006045132A (ja) | 2004-08-05 | 2006-02-16 | Konica Minolta Medical & Graphic Inc | リポソーム含有磁気共鳴造影剤 |
| US20060040980A1 (en) | 2004-08-20 | 2006-02-23 | Lind Stuart E | Ionophores as cancer chemotherapeutic agents |
| GB0423565D0 (en) * | 2004-10-22 | 2004-11-24 | Algeta As | Formulation |
| ITMI20050328A1 (it) | 2005-03-03 | 2006-09-04 | Univ Degli Studi Milano | Composti peptidomimetrici e preparazione di derivati biologicamente attivi |
| TW200922630A (en) | 2007-09-26 | 2009-06-01 | Nat Health Research Institutes | Liposome compositions useful for tumor imaging and treatment |
| WO2009140215A2 (en) | 2008-05-11 | 2009-11-19 | Geraghty, Erin | Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds |
| JP5429710B2 (ja) * | 2009-03-30 | 2014-02-26 | 独立行政法人放射線医学総合研究所 | 治療薬剤の標的部位への集積及び放出を追跡可能な治療薬剤含有リポソームおよびその製造方法 |
| EP2453927B1 (en) | 2009-07-17 | 2019-05-15 | Technical University of Denmark | Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines |
-
2011
- 2011-12-14 KR KR1020137017922A patent/KR20140092226A/ko not_active Withdrawn
- 2011-12-14 WO PCT/DK2011/050479 patent/WO2012079582A1/en not_active Ceased
- 2011-12-14 DK DK11804942.8T patent/DK2651447T3/en active
- 2011-12-14 EP EP11804942.8A patent/EP2651447B1/en not_active Not-in-force
- 2011-12-14 BR BR112013014735A patent/BR112013014735A2/pt not_active IP Right Cessation
- 2011-12-14 AU AU2011344865A patent/AU2011344865B2/en not_active Ceased
- 2011-12-14 JP JP2013543530A patent/JP5947807B2/ja not_active Expired - Fee Related
- 2011-12-14 CA CA2821024A patent/CA2821024A1/en not_active Abandoned
- 2011-12-14 RU RU2013132610/15A patent/RU2013132610A/ru not_active Application Discontinuation
- 2011-12-14 US US13/992,080 patent/US9226984B2/en not_active Expired - Fee Related
-
2015
- 2015-12-14 US US14/968,019 patent/US20160158392A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013132610A (ru) | Способ получения композиции наночастиц, содержащей металлические компоненты, и полученная этим способом композиция | |
| JP2012533523A5 (enExample) | ||
| Brasse et al. | Radiometals: towards a new success story in nuclear imaging? | |
| JP2020518674A5 (enExample) | ||
| Notni et al. | Convenient Synthesis of 68 Ga-Labeled Gadolinium (III) Complexes: Towards Bimodal Responsive Probes for Functional Imaging with PET/MRI. | |
| EP2453927B1 (en) | Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines | |
| Vanasschen et al. | Radiolabelling with isotopic mixtures of 52g/55 Mn (II) as a straight route to stable manganese complexes for bimodal PET/MR imaging | |
| CN114126654A (zh) | 作为肾保护物质的对氨基马尿酸(pah) | |
| JP2011519367A5 (enExample) | ||
| US20230138790A1 (en) | Multimodal pet/mri contrast agent and a process for the synthesis thereof | |
| Alberto | Application of technetium and rhenium in nuclear medicine | |
| KR101336071B1 (ko) | 암 진단용 ｍｒｉ／ｃｔ 이중 조영제 및 그 제조방법 | |
| EP0755385B1 (en) | Chelant compounds | |
| Ahmadi et al. | Nanoparticles labeled with gamma-emitting radioisotopes: an attractive approach for in vivo tracking using SPECT imaging | |
| Fu et al. | Directly labeling ferrite nanoparticles with Tc-99m radioisotope for diagnostic applications | |
| AU625529B2 (en) | 10-(2'-hydroxy-3'-alkoxy-1,4,7-triscarboxymethyl-1,4,7,10- tetraazacyclododecanes | |
| IE904318A1 (en) | 10-(2'-hydroxy-3'-alkoxy-1,4,7-triscarboxymethyl-1,4,7,10,¹-tetraazacyclododecanes | |
| Faust | 4.5 Medical applications of rare earth compounds | |
| KR101336073B1 (ko) | 암 진단용 ｓｐｅｃｔ／ｍｒｉ 이중 조영제 조성물 및 이를 이용한 ｓｐｅｃｔ／ｍｒｉ이중영상을 획득하는 방법 | |
| US20140227196A1 (en) | Porphyrin compounds and their use as mri contrast agents | |
| Shuvaev et al. | Metal Ions in Bio-Imaging Techniques: A Short Overview | |
| Alresheedi | Synthesis, Characterisation and Radiolabelling of Nanoparticles for Applications in Medical Imaging | |
| Guanci | Design and characterization of Ln (III)-chelates as contrast agents for clinical diagnostic techniques | |
| KR101336072B1 (ko) | 암 진단용 ｓｐｅｃｔ／ｍｒｉ 이중 조영제 및 그 제조방법 | |
| Burke | Positron emission tomography imaging agents with gallium-68: bifunctional chelators and multimodality |